Venomous snakes have various types of phospholipase A 2 inhibitory proteins (PLIs) in their circulatory system in order to protect them from attack by their own phospholipase A 2 s (PLA 2 s). Here we show the first evidence for the existence of circulating PLI against secretory PLA 2 s (sPLA 2 s) in mammals. In mouse serum, we detected specific binding activities of group IB and X sPLA 2 s (sPLA 2 -IB and sPLA 2 -X), which was in contrast with the absence of binding activities in serum prepared from mice deficient in PLA 2 receptor (PLA 2 R), a type I transmembrane glycoprotein related to the C-type animal lectin family. Western blot analysis after partial purification with sPLA 2 -IB-affinity column confirmed the identity of serum sPLA 2 binding protein as a soluble form of PLA 2 R (sPLA 2 R) that retained all of the extracellular domains of the membrane-bound receptor. Both purified sPLA 2 R and the recombinant soluble receptor having all of the extracellular portions blocked the biological functions of sPLA 2 -X, including its potent enzymatic activity and its binding to the membrane-bound receptor.
Summary
Venomous snakes have various types of phospholipase A 2 inhibitory proteins (PLIs) in their circulatory system in order to protect them from attack by their own phospholipase A 2 s (PLA 2 s). Here we show the first evidence for the existence of circulating PLI against secretory PLA 2 s (sPLA 2 s) in mammals. In mouse serum, we detected specific binding activities of group IB and X sPLA 2 s (sPLA 2 -IB and sPLA 2 -X), which was in contrast with the absence of binding activities in serum prepared from mice deficient in PLA 2 receptor (PLA 2 R), a type I transmembrane glycoprotein related to the C-type animal lectin family. Western blot analysis after partial purification with sPLA 2 -IB-affinity column confirmed the identity of serum sPLA 2 binding protein as a soluble form of PLA 2 R (sPLA 2 R) that retained all of the extracellular domains of the membrane-bound receptor. Both purified sPLA 2 R and the recombinant soluble receptor having all of the extracellular portions blocked the biological functions of sPLA 2 -X,
Introduction
Phospholipase A 2 (PLA 2 ) 1 is an enzyme that catalyzes the hydrolysis of the sn-2 ester bond of glycerophospholipids (1, 2) . Since its discovery, PLA 2 has been a molecular target of extensive research because of its critical involvement in physiological and pathological events such as phospholipid turnover and production of proinflammatory lipid mediators (3) . To date, a number of mammalian intracellular and extracellular PLA 2 s have been identified and classified into different families according to their biochemical features (4) . Among them, sPLA 2 s have several common characteristics including a relatively low molecular mass (13-18 kDa), the presence of 6 to 8 disulfide bridges, and an absolute catalytic requirement for millimolar concentrations of Ca 2+ (5, 6) . At present, mammalian sPLA 2 s are classified into ten different groups (IB, IIA, IIC, IID, IIE, IIF, III, V, X, XII) depending on the primary
Experimental Procedures
Materials.
Sodium [
125 I] iodine (carrier-free, 3.7 GBq/ml) was purchased from Amersham Pharmacia Biotech. Porcine pancreatic sPLA 2 -IB was obtained from Boehringer
Mannheim. Recombinant mouse sPLA 2 -X, recombinant soluble PLA 2 R (rsPLA 2 R) and biotin-labeled rabbit anti-sPLA 2 R antibody (Ab) were prepared as described in the previous paper (27, 28) . LPS (Salmonella Typhosa 0901) was purchased from Difco
Laboratories. Bovine serum albumin (BSA) and bovine γ-globin were purchased from Sigma. DPPC (1-palmitonyl-2-palmitonyl-sn-glycero-3-phosphocholine) was obtained from Avanti Polar Lipids, Inc., Alabaster, AL. Polyethylenglycol (PEG) 6000 was purchased from Nacalai Tesque. Protease inhibitors were obtained from Peptide Institute, Inc. and Wako Pure Chemical Industries. BB2516 was synthesized at Shionogi Research Laboratories. The generation of PLA 2 R-deficient mice was described in our previous paper (25), and they were backcrossed more than eleven times. In each experiment, C57BL/6J mice matched for gender and age were used as wild-type littermates.
Binding of sPLA 2 -IB and sPLA 2 -X to Mouse Serum.
Iodination of porcine sPLA 2 -IB or mouse sPLA 2 -X was performed by the chloramine-T method (29) , and the specific radioactivities of 125 I-sPLA 2 -IB and 125 IsPLA 2 -X were about 7000 and 4600 cpm/fmol, respectively. The serum prepared from wild-type or PLA 2 R-deficient mice (100 µl) was incubated with 3 nM 125 I-sPLA 2 -IB or filtered through Whatman GF/B glassfilter and the radioactivity of the filter was measured. Specific binding was determined as the differences between the presence and absence of unlabeled 500 nM porcine sPLA 2 -IB.
Western blot analysis of serum sPLA 2 R.
Serum sPLA 2 R was partially purified from wild-type or PLA 2 R-deficient mice with a sPLA 2 -IB-affinity column as described previously (30) , and then concentrated with ultrafree (Millipore). Chinese Hamster Ovary (CHO) cells that stably express the membrane-bound mouse PLA 2 R (PLA 2 R-CHO cells) and their crude membrane lysates were prepared as described previously (28, 29) . The serum sPLA 2 R materials, the membrane fractions of PLA 2 R-CHO or parent CHO cells, and purified rsPLA 2 R protein were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 4-20% gradient gel (Daiichi Chemical Co., Ltd.). Western blot analysis was performed according to our previous paper (27) with biotin-labeled rabbit antisPLA 2 R Ab (1 µg/ml) and streptoavidin-conjugated horseradish peroxidase (Boehringer Mannheim). The blot was incubated with a chemiluminescent detection reagent (ECL Western blotting detection reagents, Amersham Pharmacia Biotech) according to the manufacturer's instructions and analyzed using a Fluor-S MAX MultiImager (BioRad).
substrate. After incubation for 1 h at 37°C, the reaction was stopped by the addition of After cultivation in 96-well plates, PLA 2 R-CHO cells were washed three times with PBS and then incubated with or without protease inhibitors at 37°C for various times. After the incubation, the supernatant was collected by centrifugation at 8,000
rpm for 10 min at 4°C and the released sPLA 2 R was measured with established sandwich ELISA (27). In this assay, purified rsPLA 2 R was used as a conventional standard because of its molecular weight being similar to that of serum sPLA 2 R (the detection range from 0.1 to 100 ng). In separate experiments, the membranes of PLA 2 R-CHO cells were incubated in the absence or presence of protease inhibitors for 1 h at 37°C. After centrifugation at 40,000 rpm for 1 h at 4°C, the released sPLA 2 R in the supernatant was measured with sandwich ELISA.
Results

Binding of sPLA 2 s to mouse serum.
To explore the existence of circulating PLI in mammals, we first examined the binding potency of endogenous sPLA 2 s to mouse serum. We used two types of 125 Ilabeled sPLA 2 s (sPLA 2 -IB and sPLA 2 -X) and evaluated their bindings to mouse serum proteins using PEG precipitation assay. As shown in Fig. 1 , specific binding activities were detected with both ligands (10.5 fmol/ml and 7.3 fmol/ml of serum, respectively).
The specific binding linearly increased depending on the serum volume added up to lymphocytes in mice (21) . In addition, our recent analysis with sandwich ELISA suggested the presence of sPLA 2 R in mouse plasma (27). In order to examine the relationships between serum sPLA 2 binding proteins and putative sPLA 2 There are two biological responses elicited by sPLA 2 s; one is dependent on the phospholipid-hydrolyzing activity and the other is mediated via the PLA 2 R binding (17) .
Since sPLA 2 -X was proven to elicit both responses in mice (28), we next examined the effects of serum sPLA 2 R on sPLA 2 -X-induced responses. First, we examined the effects of rsPLA 2 R and serum sPLA 2 R on sPLA 2 -X enzymatic activity toward DPPC as a substrate. In this in vitro assay system, the enzyme activity of about 0.1 nM mouse sPLA 2 -X can be detected, and the purified rsPLA 2 R markedly blocked the enzymatic activity with an IC 50 value of 0.04 0.01 nM (Fig. 3A) . The acid-eluted materials prepared with sPLA 2 -IB-affinity column (Fig. 2) were found to contain the sPLA 2 R at the concentration of 0.37 nM by sandwich ELISA using rsPLA 2 R as a conventional standard. As shown in Fig. 3B , the serum sPLA 2 R fractions effectively blocked the enzymatic activity of sPLA 2 -X up to 70%, which contrasted with no significant suppression with sPLA 2 R fractions prepared from PLA 2 R-deficient mouse serum. We then examined the effect on enzymatic activity of sPLA 2 -X toward intact cell membranes. We have previously reported that mouse sPLA 2 -X induced prompt and marked release of arachidonic acid from mouse spleen cells (28) . However, a relatively higher concentration of sPLA 2 -X (over 0.5 nM) was required for detection of sufficient responses in intact cell systems. As shown in Fig. 3C , rsPLA 2 R dose-dependently blocked the arachidonic acid release evoked by mouse sPLA 2 -X (2 nM). However, significant suppression could not be observed using the serum sPLA 2 R fractions, possibly due to its lower quantities of sPLA 2 R protein (data not shown).
Next, we examined the effects of rsPLA 2 R and serum sPLA 2 R on sPLA 2 Study of the mechanisms underlying sPLA 2 R production.
In order to investigate the mechanisms underlying the production of sPLA 2 R, we used PLA 2 R-CHO cells that spontaneously release sPLA 2 R protein into the culture medium. We confirmed that sPLA 2 R protein isolated from the conditioned medium of PLA 2 R-CHO cells has the same molecular weight as the serum sPLA 2 R by western blot analysis (data not shown). As shown in Fig. 5A , the sPLA 2 R levels in the supernatant were time-dependently increased during the cultivation of PLA 2 R-CHO cells. This release response was suppressed over 80% by the addition of BB2516, a specific broadspectrum metalloproteinase inhibitor (33) , in contrast to no significant inhibition by p-APMSF, a serine protease inhibitor (34) . Next, the effects of various types of protease inhibitors were evaluated for the spontaneous release of sPLA 2 R from the membrane fractions of PLA 2 R-CHO cells in order to eliminate their toxic effects on intact cells.
The concentration used was optimized for their efficient and specific inhibition against target proteases in vitro. After incubation in the presence of inhibitors for 1 h, the released sPLA 2 R in the supernatant was evaluated with sandwich ELISA. As shown in Western blot analysis revealed that serum sPLA 2 R retained all of the extracellular domains of the membrane-bound form of the receptor being similar to rsPLA 2 R (Fig. 2) .
We have previously shown that rsPLA 2 R retained the same binding dissociation constant (Kd = 0.97 nM for sPLA 2 -IB) and ligand specificity as the membrane-bound receptor (17, 37) . Scatchard plot analysis has revealed that rsPLA 2 R can bind one sPLA 2 ligand per molecule, like the native cell-surface receptor (37) . In fact, rsPLA 2 R protein strongly blocked the sPLA 2 -X binding to the membrane-bound receptor with an IC 50 value of 1.2 nM (Fig. 4A ), which coincided with the binding affinity of sPLA 2 -X to the cell-surface PLA 2 R (21). In the present study, serum sPLA 2 R was found to possess binding activity for sPLA 2 -IB and sPLA 2 -X (Fig. 1 ). In addition, serum sPLA 2 R blocked the enzymatic activity and receptor binding activity of sPLA 2 -X ( Fig. 3B and   4B ). These findings demonstrate that serum sPLA 2 R has similar characteristics with rsPLA 2 R in terms of biochemical properties as well as functional activities, and thus confirmed our previous estimation of the plasma sPLA 2 R concentration in normal mice with sandwich ELISA (0.13 nM), in which rsPLA 2 R was used as a conventional standard (27).
We have previously reported that sPLA 2 toward the substrate DPPC (Fig. 3A) , and the prepared serum sPLA 2 R fractions (0.37 nM) was found to suppress the activity up to 70% (Fig. 3B) . However, in mouse spleen cells, the inhibitory potency of rsPLA 2 R for sPLA 2 -X-induced arachidonic acid release was weaker compared to that in the DPPC hydrolysis, possibly due to the requirement of higher concentration of sPLA 2 -X for detection of the released fatty acids in intact cell systems. For the sPLA 2 -X binding, rsPLA 2 R was found to block up to 20% at the normal circulating concentration (Fig. 4A) , and its inhibitory potency can be greatly enhanced at the concentration over 0.3 nM. In fact, the concentrated serum materials containing higher levels of sPLA 2 R (1.36 nM) could significantly block the sPLA 2 -X binding (Fig. 4B) . It has been reported that the normal serum concentration of sPLA 2 -IB is 5.1 ng/ml (0.36 nM) in humans (40). Although the normal plasma level of sPLA 2 -IB and sPLA 2 -X has not yet been examined in mice, these findings suggest that the circulating sPLA 2 R can play one of the endogenous inhibitors that block the biological functions of these sPLA 2 s in the normal conditions. In patients with acute pancreatitis and renal failure, increased systemic levels of sPLA 2 Further studies with specific inhibitors should help identify the metalloproteinase types involved.
In conclusion, we have identified circulating sPLA 2 R as an endogenous inhibitor of sPLA 2 s in mice. In this study, the use of PLA 2 R-deficient mice has enabled us to clearly show the existence of the receptor in serum. Since there is strict species specificity in the relationships between sPLA 2 ligands and PLA 2 R, further studies on the identification of sPLA 2 R and its ligand in humans are required for elucidation of their physiological and pathological roles. 
